SOPHiA GENETICS SA (NASDAQ:SOPH) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET
Company Participants
Katherine Bailon - Head, Investor Relations
Dr. Jurgi Camblong - Co-Founder and CEO
Ross Muken - Chief Financial Officer and COO
Conference Call Participants
Edmund Tu - Morgan Stanley
Dan Brennan - TD Cowen
Rachel Vatnsdal - JPMorgan
Vidyun Bais - BTIG
Operator
Hello, ladies and gentlemen. And thank you for joining SOPHiA GENETICS Second Quarter 2020 Earnings Call. Our host for today is Katherine Bailon, Head of Investor Relations. Ms. Bailon, you may begin.
Katherine Bailon
Good morning. And thank you for joining us on SOPHiA GENETICS second quarter fiscal 2023 earnings call. My name is Katherine Bailon, and I am the Head of Investor Relations at SOPHiA GENETICS. Joining me today are Dr. Jurgi Camblong, our Co-Founder and Chief Executive Officer; and Ross Muken, our Chief Financial Officer and Chief Operating Officer.
Before we get started, I’d like to remind you that the management team will make statements during this call that are forward-looking within the meaning of United States federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.
Additional information regarding these risks and uncertainties appears in the section entitled Cautionary Statement Regarding Forward-Looking Statements in the Form 6-K for the second quarter earnings release on file with the SEC.
Except as required by law, SOPHiA GENETICS disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of its broadcast, August 8, 2023.
This presentation includes non-IFRS financial measures. These measures are calculated by management and do not have any standardized meaning under IFRS. These non-IFRS measures supplement IFRS measures, but should not be viewed as substitutes for IFRS measures. We have included a reconciliation of IFRS measures to non-IFRS measures in our press release issued this morning, which is available on our website.
Please note, both the replay of this call and the earnings release will be available on our website in the Investor Relations section.
And with that, now I will turn it over to Jurgi.
Dr. Jurgi Camblong
Thank you, Katherine, and good morning, everyone. We appreciate you joining us on our call today. I am pleased to share that our second quarter results came in strong, with total revenue for the second quarter growing 30% year-over-year on a constant currency basis after adjusting for COVID-19-related revenues.